ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
- Conditions
- Chronic Hepatitis CHepatitis C Genotype 1Hepatitis C (HCV)
- Interventions
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 580
- Registration Number
- NCT01464827
- Locations
- 🇺🇸
Site Reference ID/Investigator# 55527, Marietta, Georgia, United States
🇺🇸Site Reference ID/Investigator# 43661, Jackson, Mississippi, United States
🇺🇸Site Reference ID/Investigator# 56622, Philadelphia, Pennsylvania, United States
A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China
- Conditions
- RheumatoidArthritis
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 26
- Registration Number
- NCT01464021
- Locations
- 🇨🇳
Site Reference ID/Investigator# 65706, Wulumuqi, China
🇨🇳Site Reference ID/Investigator# 64782, Guangzhou City, China
🇨🇳Site Reference ID/Investigator# 65702, Shanghai, China
Special Investigation (Long-term Investigation) in Patients With Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 511
- Registration Number
- NCT01464333
A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 61
- Registration Number
- NCT01458535
A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: ABT-652 NSAIDDrug: Placebo NSAID
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 202
- Registration Number
- NCT01444365
- Locations
- 🇺🇸
Site Reference ID/Investigator# 61257, Anaheim, California, United States
🇺🇸Site Reference ID/Investigator# 61226, Phoenix, Arizona, United States
🇺🇸Site Reference ID/Investigator# 61235, San Antonio, Texas, United States
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
- Conditions
- Heavy Uterine BleedingUterine Fibroids
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 271
- Registration Number
- NCT01441635
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab
- Conditions
- Severe Crohn's DiseaseAnxiety
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 83
- Registration Number
- NCT01428115
- Locations
- 🇦🇹
Site Reference ID/Investigator# 47342, Vienna, Austria
🇦🇹Site Reference ID/Investigator# 79613, St. Veit/Glan, Austria
🇦🇹Site Reference ID/Investigator# 64830, Graz, Austria
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
- Conditions
- Chronic Kidney DiseaseDiabetic Nephropathy
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 58
- Registration Number
- NCT01424319
- Locations
- 🇯🇵
Site Reference ID/Investigator# 55093, Kawagoe, Japan
🇯🇵Site Reference ID/Investigator# 56524, Matsumoto, Japan
🇯🇵Site Reference ID/Investigator# 55095, Yokohama, Japan
An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 35
- Registration Number
- NCT01413893
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
- Conditions
- Arthritis, Juvenile Rheumatoid
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 375
- Registration Number
- NCT01412021